9 completed, 5 recruiting, 4 terminated, 2 active not recruiting. 12 Phase 2, 6 Phase 1, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Recruiting 4, Completed 3, Terminated 3, Active not recruiting 2 |
| Phase 1 | 6 | Completed 3, Terminated 3 |
| Not applicable | 4 | Completed 3, Withdrawn 1 |
Follow Giselle Sholler: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Tipifarnib, Naxitamab - Neuroblastoma | Phase 2 | Recruiting | Giselle Sholler | 98 | 2024-12-06 | 2026-09-03 |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma Naxitamab - Neuroblastoma | Phase 2 | Recruiting | Giselle Sholler | 93 | 2022-09-14 | 2026-08-12 |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma Difluoromethylornithine - Medulloblastoma | Phase 2 | Recruiting | Giselle Sholler | 118 | 2021-03-29 | 2026-08-12 |
| Beat Childhood Cancer Specimen Banking and Data Registry No intervention- registry only - Pediatric Cancer, Survivorship | Recruiting | Giselle Sholler | 1000 | 2021-02-02 | 2026-02-03 | |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Eflornithine - Neuroblastoma | Phase 2 | Active not recruiting | Giselle Sholler | 131 | 2020-09-25 | 2026-09-03 |
| Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS) - Relapsed Neuroblastoma | Not applicable | Withdrawn | Giselle Sholler | 2017-05-01 | 2023-09-28 | |
| Neuroblastoma Maintenance Therapy Trial Difluoromethylornithine (DFMO) - Neuroblastoma | Phase 2 | Active not recruiting | Giselle Sholler | 441 | 2016-02-01 | 2026-09-03 |
| Trial of Tolcapone With Oxaliplatin for Neuroblastoma Tolcapone, Oxaliplatin - Neuroblastoma | Phase 1 | Terminated | Giselle Sholler | 5 | 2015-12-01 | 2024-08-06 |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Ceritinib, dasatinib, sorafenib - Neuroblastoma | Phase 2 | Recruiting | Giselle Sholler | 500 | 2015-09-01 | 2026-09-04 |
| Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission DFMO - Neuroblastoma | Phase 2 | Completed | Giselle Sholler | 140 | 2015-03-05 | 2024-08-06 |
| Molecular-Guided Therapy for Childhood Cancer Guided Therapy - Neuroblastoma, Medulloblastoma | Not applicable | Completed | Giselle Sholler | 186 | 2014-07-08 | 2025-11-03 |
| Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma DFMO, Bortezomib - Neuroblastoma Recurrent | Phase 1 / Phase 2 | Completed | Giselle Sholler | 16 | 2014-06-06 | 2024-08-06 |
| Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma Vismodegib - Pontine Glioma | Phase 2 | Terminated | Giselle Sholler | 9 | 2013-05-01 | 2024-08-06 |
| Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Guided Therapy- Pediatric Gene Analysis Platform - Neuroblastoma, Medulloblastoma | Not applicable | Completed | Giselle Sholler | 52 | 2013-03-04 | 2024-08-06 |
| Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 8 | 2011-12-01 | 2024-08-06 |
| Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma TPI 287, Temozolomide, Irinotecan - Neuroblastoma | Phase 1 / Phase 2 | Terminated | Giselle Sholler | 14 | 2011-12-01 | 2024-08-06 |
| Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma Guided Therapy - Neuroblastoma | Not applicable | Completed | Giselle Sholler | 16 | 2011-05-01 | 2024-08-06 |
| A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma Refractory Neuroblastoma, Relapsed Neuroblastoma | Completed | Giselle Sholler | 5 | 2010-04-01 | 2024-08-06 | |
| Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide DFMO, Etoposide - Neuroblastoma | Phase 1 | Completed | Giselle Sholler | 21 | 2010-02-01 | 2024-08-06 |
| TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma TPI 287 - Neuroblastoma, Medulloblastoma | Phase 1 | Completed | Giselle Sholler | 18 | 2009-03-01 | 2024-08-06 |
Showing 20 of 22. Sign in to see all of them.
Neuroblastoma (18) · Medulloblastoma (7) · Neuroectodermal Tumors, Primitive (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Choroid Plexus Neoplasms (1) · Craniopharyngioma (1) · Ependymoma (1) · Glioma (1) · Meningioma (1) · Neoplasms (1) · Neoplasms, Germ Cell and Embryonal (1) · Osteosarcoma (1) · Recurrence (1)
Eflornithine (8) · TPI-287 (3) · Radiotherapy, Image-Guided (2) · naxitamab (2) · Bortezomib (1) · Cyclophosphamide (1) · Dasatinib (1) · Etoposide (1) · HhAntag691 (1) · Irinotecan (1) · Nifurtimox (1) · Oxaliplatin (1) · Radiation (1) · Sorafenib (1) · Spermine Synthase (1)
United States (22) · Canada (5) · Brazil (1) · Lebanon (1) · Spain (1)
Albert Cornelius, MD (1) · Don Eslin, MD (1) · Giselle Saulnier-Sholler, MD (1) · Jaqueline Kraveka, DO (1) · Jessica Foley, MD (1) · Kathleen Neville, MD (1) · Kaveh Asadi-Moghaddam, MD (1) · Michael A Huang, MD (1) · Nehal Parikh, MD (1) · Valerie Brown, MD, PhD (1)
PMID 38917371, PMID 26018967, PMID 32391579, PMID 32506485, PMID 34522028, PMID 37883734, PMID 38347552